By 1969, Gibson’s Maestro division contracted Oberheim Electronics to build his ring modulator for them, which was marketed as the Maestro RM-1A. The ring modulator had limited appeal to the masses ...

Quantum materials, materials exhibiting physical behavior governed by the laws of quantum mechanics, have proved promising ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

Durable ZUMA-2 follow-up converted brexu-cel to traditional approval in r/r MCL, while sonrotoclax gained accelerated approval post-BTK inhibitor based on 52% ORR. Breast-cancer decisions expanded ...

The development of the 6G standard is entering a more concrete phase. At the June 2026 3GPP RAN Plenary in Singapore, the industry advanced several key areas under study and finalized the timeline for ...

Bupropion conferred modest reductions in cancer-related fatigue compared with placebo, according to results of a randomized ...

Summary: Patients surviving severe traumatic brain injuries often enter states designated as Prolonged Disorders of ...

You'll come for the hands-on tweaking and wealth of features, and quickly forgive some of the workflow issues when you hear ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...

Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its ...